All In Biotech

Drug Trial Radar · NCT07073820

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

A PHASE 2, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-07868489 ADMINISTERED TO ADULT PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

42

Actual

Start

Nov 10, 2025

Primary completion

Oct 9, 2026

Study completion Oct 9, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Conditions

  • Pulmonary Hypertension

Interventions

  • PF-07868489Drug

    Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to week 111
  2. Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline up to week 111
  3. Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to week 111

Locations

27 sites in 10 countries. Site status is shown where the registry gives one.

  • UCSF Health St. Mary's Hospital

    San Francisco, California

  • Heart and Vascular Center

    San Francisco, California

  • UCSF Helen Diller Medical Center at Parnassus Heights

    San Francisco, California

  • Mount Sinai Hospital

    New York, New York

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Pulmonary Hypertension Research Queensland Pty Ltd

    Auchenflower, Queensland, Australia

  • HUB Hôpital Erasme

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Thoraxklinik-Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Bavaria, Germany

  • Universitaetsklinikum Giessen und Marburg GmbH

    Giessen, Hesse, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Mecklenburg-Vorpommern, Germany

  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

    Dresden, Saxony, Germany

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, Japan

  • Gachon University Gil Medical Center

    Incheon, Incheon-gwangyeoksi [incheon], South Korea

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [seoul], South Korea

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi [seoul], South Korea

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hammersmith Hospital

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.